Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 19;2(5):1546-1555.
doi: 10.1039/d1cb00134e. eCollection 2021 Oct 7.

Macrocyclic peptides as allosteric inhibitors of nicotinamide N-methyltransferase (NNMT)

Matthijs J van Haren  1 , Yurui Zhang  1 , Vito Thijssen  2 , Ned Buijs  1 , Yongzhi Gao  1 , Lukasz Mateuszuk  3 , Filip A Fedak  3 , Agnieszka Kij  3 , Roberto Campagna  4 , Davide Sartini  4 , Monica Emanuelli  4 , Stefan Chlopicki  3   5 , Seino A K Jongkees  2   6 , Nathaniel I Martin  1
Affiliations

Macrocyclic peptides as allosteric inhibitors of nicotinamide N-methyltransferase (NNMT)

Matthijs J van Haren et al. RSC Chem Biol. .

Abstract

Nicotinamide N-methyltransferase (NNMT) methylates nicotinamide to form 1-methylnicotinamide (MNA) using S-adenosyl-l-methionine (SAM) as the methyl donor. The complexity of the role of NNMT in healthy and disease states is slowly being elucidated and provides an indication that NNMT may be an interesting therapeutic target for a variety of diseases including cancer, diabetes, and obesity. Most inhibitors of NNMT described to date are structurally related to one or both of its substrates. In the search for structurally diverse NNMT inhibitors, an mRNA display screening technique was used to identify macrocyclic peptides which bind to NNMT. Several of the cyclic peptides identified in this manner show potent inhibition of NNMT with IC50 values as low as 229 nM. The peptides were also found to downregulate MNA production in cellular assays. Interestingly, substrate competition experiments reveal that these cyclic peptide inhibitors are noncompetitive with either SAM or NA indicating they may be the first allosteric inhibitors reported for NNMT.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts to declare.

Figures

Fig. 1
Fig. 1. Schematic overview of the RaPID mRNA display system used to translate a random DNA library (>1012 library members, 17 residues), affording a large peptide library whose members were selected for binding affinity against NNMT. Selections initiated with either N-chloroacetyl-l-tyrosine or N-chloroacetyl-d-tyrosine were performed to introduce additional structural diversity in the library. The four cyclic peptides indicated at the bottom of the figure are the most potent NNMT inhibitors identified in the present study (see Table 1).
Scheme 1
Scheme 1. General synthesis route for the preparation of cyclic peptides identified from the mRNA display screen. The identified peptides identified all contain 18 amino acids (including a single additional C-terminal glycine for efficient synthesis).
Fig. 2
Fig. 2. Results of the substrate competition experiment. The data is normalized per compound by setting the IC50 under normal assay conditions at 1. Data is based on duplicate data of at least 7 different concentrations. Structures of control compounds X and Y are presented on the left. Full IC50 curves are presented in Fig. S6 and S7 in the ESI.
Fig. 3
Fig. 3. Cellular activity of cyclic peptides 4 and 13 and small molecule reference compound 6-methylamino-nicotinamide (6-MANA) against A549 lung carcinoma cells (left) and human aortic endothelial cells (HAEC, right). Data is based on six replicates. The results indicate a significant reduction of MNA concentration compared to untreated cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alston T. A. Abeles R. H. Substrate specificity of nicotinamide methyltransferase isolated from porcine liver. Arch. Biochem. Biophys. 1988;260:601–608. - PubMed
    1. van Haren M. J. Sastre Toraño J. Sartini D. Emanuelli M. Parsons R. B. Martin N. I. A Rapid and Efficient Assay for the Characterization of Substrates and Inhibitors of Nicotinamide N-Methyltransferase. Biochemistry. 2016;55:5307–5315. - PubMed
    1. Ulanovskaya O. A. Zuhl A. M. Cravatt B. F. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat. Chem. Biol. 2013;9:300–306. - PMC - PubMed
    1. Eckert M. A. Coscia F. Chryplewicz A. Chang J. W. Hernandez K. M. Pan S. Tienda S. M. Nahotko D. A. Li G. Blaženović I. Lastra R. R. Curtis M. Yamada S. D. Perets R. McGregor S. M. Andrade J. Fiehn O. Moellering R. E. Mann M. Lengyel E. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019;569:723–728. - PMC - PubMed
    1. Kanakkanthara A. Kurmi K. Ekstrom T. L. Hou X. Purfeerst E. R. Heinzen E. P. Correia C. Huntoon C. J. O’Brien D. Wahner Hendrickson A. E. Dowdy S. C. Li H. Oberg A. L. Hitosugi T. Kaufmann S. H. Weroha S. J. Karnitz L. M. BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. Cancer Res. 2019;79:5920–5929. - PMC - PubMed